SANDOZ TAPS FORMER COO TIM ROTHWELL TO SUCCEED REJEANGE AS CEO
Executive Summary
SANDOZ TAPS FORMER COO TIM ROTHWELL TO SUCCEED REJEANGE AS CEO, the company announced June 23. Rothwell, 41, worked for Sandoz between 1972 and 1989, last serving as chief operating officer of Sandoz' U.S. pharmaceutical division. He will rejoin Sandoz in early July, replacing Jacques Rejeange, who resigned two weeks ago after 26 years with the company to head Kodak's Sterling Winthrop Pharmaceuticals ("The Pink Sheet" June 18, T&G-3). Rothwell left Sandoz to become vice-president and general manager of Squibb's Pharmaceuticals Division in 1989. He joined Burroughs Wellcome in June 1991, where he has been serving as VP-marketing and sales. "Tim Rothwell is rejoining Sandoz Pharmaceuticals at a time when the company is pursuing an extensive program of expansion and cooperative ventures in the U.S.," Sandoz Chairman Daniel Wagniere said. "He is eminently qualified to lead this effort and we welcome him back among us." Over the last year, Sandoz has been active in start-up investments and collaborative deals with U.S. firms and began trading depository shares in the U.S. last November. However, Sandoz also has been experiencing a management drain in its U.S. operations, beginning with the departure of Fred Hassan in 1989, who left to head Wyeth- Ayerst. More recently, Sandoz Research President Robert Levy, Senior VP-R&D Manfred Karobath and Rejeange also have resigned. In a separate same-day release, Burroughs Wellcome announced that Rothwell would be replaced by Lederle Pharmaceuticals VP and General Manager Mark Perrin, who has experience in sales and marketing as well as product management for anti-infectives, vaccines and biological products. Lederle has not yet announced Perrin's replacement.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth